Tivozanib (Compound)

Synonyms:Tivozanib, 475108-18-0, AV-951, Tivozanib (AV-951), KRN-951, AV 951, AV951, 1-(2-Chloro-4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-3-(5-methylisoxazol-3-yl)urea, KRN951, fotivda, N-[2-CHLORO-4-[(6,7-DIMETHOXY-4-QUINOLYL)OXY]PHENYL]-N'-(5-METHYL-3-ISOXAZOLYL)UREA, KIL8951, KRN 951, C22H19ClN4O5, Kil-8951, CHEMBL1289494, AV-951;KRN951, 1-(2-CHLORO-4-(6,7-DIMETHOXYQUINOLIN-4-YLOXY)PHENYL)-3-(5-METHYLISOXAZOL-3-YL)UREA, 1-[2-chloro-4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-3-(5-methyl-1,2-oxazol-3-yl)urea, 172030934T, 1-(2-Chloro-4-((6,7-dimethoxyquinolin-4-yl)-oxy)phenyl)-3-(5-methylisoxazol-3-yl)urea, 1-{2-chloro-4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-3-(5-methyl-1,2-oxazol-3-yl)urea, N-(2-Chloro-4-((6,7-dimethoxy-4-quinolyl)oxy)phenyl)-N'-(5-methyl-3-isoxazolyl)urea, Urea, N-(2-chloro-4-((6,7-dimethoxy-4-quinolinyl)oxy)phenyl)-N'-(5-methyl-3-isoxazolyl)-, Tivozanib [USAN], ASP-4130, Tivozanib [USAN:INN], 4ase, N-{2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl-3-isoxazolyl)urea, AV9, UNII-172030934T, AV-951,Tivozanib, Tivozanib(AV-951), TIVOZANIB [INN], AV951 cpd, Tivozanib (USAN/INN), Tivozanib - AV-951, TIVOZANIB [WHO-DD], MLS006011287, SCHEMBL172883, GTPL6058, CHEBI:91327, DTXSID20963865, EX-A472, HMS3229O09, HMS3244C19, HMS3244C20, HMS3244D19, HMS3265A11, HMS3265A12, HMS3265B11, HMS3265B12, HMS3654G22, HMS3745C05, AMY39975, BCP01980, VEGFR Tyrosine Kinase Inhibitor IV, BDBM50331095, MFCD15146788, NSC758007, NSC800952, s1207, AKOS022177607, AV951 (KRN951, TIVOZANIB), BCP9000343, CCG-206805, CS-0103, DB11800, EX-8600, NSC-758007, NSC-800952, PB28569, NCGC00249390-01, NCGC00249390-05, NCGC00249390-12, AC-24702, AS-16997, BT160380, HY-10977, SMR004703037, FT-0700315, SW219364-1, A24970, D09683, EN300-18167318, J-502964, Q7810457, BRD-K53414658-001-01-7, N-{2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)-oxy]phenyl}-N'-(5-methyl-3-isoxazolyl)urea, 1-(2-chloro-4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-3-(5-methylisoxazol-3-yl)urea;AV-951, N-(2-CHLORO-4-((6,7-DIMETHOXYQUINOLIN-4-YL)OXY)PHENYL)-N'-(5-METHYLISOXAZOL-3-YL)UREA

Pubchem:PUBCHEM:9911830

Id:bce8e01c-874d-5a4a-bb40-80398b919bfc

Description:nan

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View Tivozanib's neighborhood in the knowledge graph.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for Tivozanib.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with Tivozanib.

Results found

Linked to

	Label	Description
	BRD-K53414658-001-08-2 Substance (Entity type)	A Substance
	DCSTRUCT ID 05258 Collection (Entity type)	DrugPage Collection: (DrugCentralID:05258; PubChem_CID:9911830, FILE=drugcentral_drug_05258.json)
	tivozanib (43577080-470f-417a-a4b4-a69b96e60202) Collection (Entity type)	Metadatata for tivozanib
	Tivozanib negatively regulates TFPI2 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	Tivozanib positively regulates CHAC1 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	Tivozanib negatively regulates ADORA2B Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	Tivozanib bioactivity Vascular endothelial growth factor receptor 1 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from IDG
	Tivozanib negatively regulates KLF10 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	Tivozanib positively regulates SOX4 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	Tivozanib negatively regulates PNP Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS